Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31195423 | 1.00 | HTT (0.46) | HTTCYP2C19ALDH1A1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL4476848 | 0.98 | HTT (0.45) | HTTCYP2C19ALDH1A1NPC1RAB9A | |
| SCHEMBL4098037 | 0.87 | HTT (0.51) | HTTCYP2C19ALDH1A1NPC1RAB9A | |
| SCHEMBL4095279 | 0.86 | SMN1; SMN2 (0.40) | HTTALDH1A1SMN1; SMN2CA9PKM | |
| SCHEMBL9316696 | 0.85 | HTT (0.51) | HTTCYP2C19ALDH1A1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL16702112 | 0.85 | SMN1; SMN2 (0.39) | HTTALDH1A1SMN1; SMN2CA9PKM | |
| SCHEMBL11412037 | 0.83 | SIGMAR1 (0.46) | HTTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL11320624 | 0.83 | RAB9A (0.56) | HTTCYP2C19ALDH1A1NPC1RAB9A | |
| SCHEMBL12838551 | 0.83 | NPC1 (0.40) | ALDH1A1NPC1RAB9ASMN1; SMN2CA12 | |
| SCHEMBL11835923 | 0.83 | MAP2K2 (0.40) | HTTCA1CA2CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10716771-B2 | Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC CORPORATION FOUNDATION (KR) | 2020-07-21 | — | — | US | claimed |
| US-20190328685-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASES OR INFLAMMATORY DISEASES, CONTAINING BIGUANIDE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2019-10-31 | — | — | US | claimed |
| US-20170333370-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASES OR INFLAMMATORY DISEASES, CONTAINING BIGUANIDE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2017-11-23 | — | — | US | claimed |
| EP-0507317-A2 | Biguanide derivatives, manufacturing method thereof, and disinfectants containing the derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-07 | — | — | EP | claimed |
| US-20240374545-A1 | DIAGNOSIS OF IMMUNITY REDUCTION THROUGH INTESTINAL MICROFLORA ANALYSIS OF STOMACH CANCER PATIENTS, AND THERAGNOSTIC COMPOSITION USING INTESTINAL MICROFLORA | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2024-11-14 | — | — | US | disclosed |
| WO-2024143583-A1 | THERAPEUTIC INJECTION COMPOSITION FOR IMMUNOREGULATION IN OSTEOARTHRITIS SYNOVIAL JOINT | 가톨릭대학교 산학협력단 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024143583-A1 | THERAPEUTIC INJECTION COMPOSITION FOR IMMUNOREGULATION IN OSTEOARTHRITIS SYNOVIAL JOINT | 가톨릭대학교 산학협력단 | 2024-07-04 | — | — | WO | disclosed |
| WO-2023140721-A1 | DIAGNOSIS OF IMMUNITY REDUCTION THROUGH INTESTINAL MICROFLORA ANALYSIS OF STOMACH CANCER PATIENTS, AND THERAGNOSTIC COMPOSITION USING INTESTINAL MICROFLORA | 가톨릭대학교 산학협력단 | 2023-07-27 | — | — | WO | disclosed |
| WO-2023140721-A1 | DIAGNOSIS OF IMMUNITY REDUCTION THROUGH INTESTINAL MICROFLORA ANALYSIS OF STOMACH CANCER PATIENTS, AND THERAGNOSTIC COMPOSITION USING INTESTINAL MICROFLORA | 가톨릭대학교 산학협력단 | 2023-07-27 | — | — | WO | disclosed |
| WO-2023136698-A1 | BIGUANIDE COMPOSITION IN WHICH LUPUS-CAUSING B CELLS AND IMMUNOSUPPRESSANT HAVING ANTIBODY MODULATION EFFECT ARE COMBINED | 가톨릭대학교 산학협력단 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023136698-A1 | BIGUANIDE COMPOSITION IN WHICH LUPUS-CAUSING B CELLS AND IMMUNOSUPPRESSANT HAVING ANTIBODY MODULATION EFFECT ARE COMBINED | 가톨릭대학교 산학협력단 | 2023-07-20 | — | — | WO | disclosed |
| WO-2022092915-A1 | COMPOSITION FOR PREVENTING AND TREATING IMMUNE DISEASES CONTAINING GDF15 AS ACTIVE INGREDIENT | 가톨릭대학교 산학협력단 | 2022-05-05 | — | — | WO | disclosed |
| US-20090123513-A1 | Antimicrobial Biguanide Metal Complexes | SMITH & NEPHEW PLC (GB) | 2009-05-14 | — | — | US | disclosed |
| EP-1902059-A1 | ANTIMICROBIAL BIGUANIDE METAL COMPLEXES | Smith & Nephew, PLC (GB) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007000590-A1 | ANTIMICROBIAL BIGUANIDE METAL COMPLEXES | SMITH & NEPHEW PLC (GB) | 2007-01-04 | — | — | WO | disclosed |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | L'OREAL S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | L'OREAL | 2005-06-16 | — | — | US | disclosed |
| EP-1532963-A1 | Composition for straightening the hair comprising at least one imine not being an hydroxide | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| EP-1532960-A1 | Hair styling composition containing a non-hydroxide imine | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| CN-1065453-A | Biguanide derivative, its manufacture method and the Herb of Common violet that contains this derivative | OTSUKA CHEMICAL CO LTD (JP) | 1992-10-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123513-A1 | Antimicrobial Biguanide Metal Complexes | GLMN, SOD1, MB | HTT 3937/4885CYP2C19 1265/4885ALDH1A1 2475/4885 |
| US-10716771-B2 | Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient | IL17A, TNF, IL2 | HTT 1585/4885CYP2C19 995/4885ALDH1A1 2223/4885 |
| US-20170333370-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASES OR INFLAMMATORY DISEASES, CONTAINING BIGUANIDE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | IL17A, TNF, IL2 | HTT 1585/4885CYP2C19 995/4885ALDH1A1 2223/4885 |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | KRT18, INHA, H1-5 | HTT 1124/4885CYP2C19 2413/4885ALDH1A1 1073/4885 |
| US-20190328685-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASES OR INFLAMMATORY DISEASES, CONTAINING BIGUANIDE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | IL17A, TNF, IL2 | HTT 1585/4885CYP2C19 995/4885ALDH1A1 2223/4885 |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | BHMT, KRT18, INMT | HTT 1588/4885CYP2C19 2856/4885ALDH1A1 1610/4885 |
| US-20240374545-A1 | DIAGNOSIS OF IMMUNITY REDUCTION THROUGH INTESTINAL MICROFLORA ANALYSIS OF STOMACH CANCER PATIENTS, AND THERAGNOSTIC COMPOSITION USING INTESTINAL MICROFLORA | FABP6, SLC10A2, FABP2 | HTT 4012/4885CYP2C19 775/4885ALDH1A1 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.